EMA Recommends Granting a Marketing Authorisation for Zolbetuximab
It is intended for the treatment of CLDN18.2-positive gastric or gastro-oesophageal junction adenocarcinoma
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Adding Upfront SRS to CNS-penetrant TKI Improves Time-to-CNS Progression and Local CNS Control, But Not OS, in Patients with Brain Metastases from EGFR- and ALK-driven NSCLC
Findings from the TURBO-NSCLC study
Comprehensive Genomic Profiling with Molecularly-Guided Therapy Results in Longer PFS Compared with Platinum-based Chemotherapy in Patients with CUP
Findings from the CUPISCO study
EMA Recommends Extension of Therapeutic Indications for Encorafenib and Binimetinib
The combination is indicated for the treatment of adult patients with advanced NSCLC with a BRAF V600E mutation
Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in Uveal Melanoma
Findings from the COOG2 study
EMA Recommends Granting a Marketing Authorisation for Toripalimab
It is intended for the first-line treatment of patients with nasopharyngeal carcinoma and oesophageal squamous cell carcinoma
Preliminary Evidence of Efficacy of an Upfront ICI-based Therapeutic Strategy in pMMR mCRC with Supporting Findings from Translational Analyses
Results from the AtezoTRIBE study
Neoadjuvant Docetaxel, Oxaliplatin, and S-1, as Part of Perioperative Chemotherapy, Prolongs Survival in Asian Patients with Locally Advanced Gastric Cancer
Findings from the long-term follow-up analysis of the PRODIGY study
EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib
Nilotinib Accord is a generic of Tasigna, which has been authorised in the EU since 2007
Neoadjuvant Chemotherapy with mFOLFIRINOX Followed by Chemoradiotherapy Improves Survival in Patients with Locally Advanced Rectal Cancer
Findings from the long-term follow-up analysis of the UNICANCER-PRODIGE 23 study
Virchow: The Largest Foundation Model for Computational Pathology To Date
Aiming to develop a single model to detect cancer, including rare cancers
Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in MRD-negative Remission from BCP-ALL
Findings from E1910 study